{"id":390887,"date":"2017-10-10T00:00:00","date_gmt":"2017-10-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreon0030-2017-biopharma-supportive-care-in-oncology-access-and-reimbursement-us-2017\/"},"modified":"2026-04-17T11:40:32","modified_gmt":"2026-04-17T11:40:32","slug":"acreon0030-2017-biopharma-supportive-care-in-oncology-access-and-reimbursement-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreon0030-2017-biopharma-supportive-care-in-oncology-access-and-reimbursement-us-2017\/","title":{"rendered":"Supportive Care in Oncology | Access and Reimbursement | US | 2017"},"content":{"rendered":"<p>The treatment of both solid and hematological cancers is associated with a wide range of serious side effects, including chemotherapy-associated\u00a0neutropenia and\u00a0anemia, nausea and vomiting, and oral mucositis. In addition to some of these adverse events being life-threatening, they\u00a0have a significant detrimental impact on patients\u2019 quality of life and often require dose delays, dose reductions, or cessation of cancer treatment, thereby compromising outcomes. As a result, the optimal treatment of chemotherapy-related side effects using supportive care therapies is an integral part of good cancer patient care.\u00a0 Clinical factors play a critical role in supportive therapy choice, but payer restrictions also shape prescribing decisions.\u00a0Emerging therapy and biosimilar pricing will have a significant impact on MCO coverage in commercial plans in the near future. A significantly lower price than the standard of care features\u00a0prominently among the top\u00a0most important attributes for development of new supportive care therapies, both according to surveyed payers and physicians.<\/p>\n","protected":false},"template":"","class_list":["post-390887","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390887\/revisions"}],"predecessor-version":[{"id":394011,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390887\/revisions\/394011"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}